Advertisement

Clinical and Experimental Medicine

, Volume 19, Issue 3, pp 393–400 | Cite as

Mutation analysis of POLE gene in patients with early-onset colorectal cancer revealed a rare silent variant within the endonuclease domain with potential effect on splicing

  • Zora LasabováEmail author
  • Michal Kalman
  • Veronika Holubeková
  • Marián Grendár
  • Ivana Kašubová
  • Karin Jašek
  • Sandra Meršaková
  • Bibiana Malicherová
  • Denis Baranenko
  • Mariusz Adamek
  • Peter KruzliakEmail author
  • Lukáš Plank
Original Article
  • 186 Downloads

Abstract

The colorectal cancer harbor germline, somatic or epimutations in mismatch repair genes, MUTYH or POLE gene, which lead to the hypermutated and ultramutator phenotypes with increased immune response. The mutations in POLE gene were reported to occur more frequently in early-onset colorectal cancer (EOCRC), and the patients are strong candidates for checkpoint inhibitor therapy. Here, we report mutation analysis within the endonuclease domain of the POLE gene in the cohort of patients with EOCRC in order to identify recurrent or new mutations and evaluate their association with the presence of tumor-infiltrating lymphocytes (TILs) and peritumoral lymphoid reaction. We have shown a significant association between MSI tumors and TILs (p = 0.004). Using sensitive single-tube nested PCR with subsequent Sanger sequencing, we have found in one female patient diagnosed at age 48 with rectal adenocarcinoma with mucinous elements staged pT3pN2pM1 a silent variant within the exon 9 NM_006231.3 c.849 C > T, NP_00622.2 p.Leu283 = recorded in dSNP as rs1232888774 with MAF = 0.00002. In silico prediction, result showed possible involvement into splicing; therefore, this rare variant can be involved into EOCRC pathogenesis. In the time of precise medicine, it is important to develop screening strategies also for less common conditions such as EOCRC allowing to predict tailored therapy for younger patients suffering from CRC that harbor mutations in the POLE gene.

Keywords

Early-onset colorectal cancer POLE mutations Microsatellite instability Tumor-infiltrating lymphocytes 

Notes

Funding

This study was supported by the Biomedical center Martin (ITMS 26220220187), which is co-financed from EU sources, by Government of Russian Federation, Grant 08-08, and by the projects of the Slovak Research and development Agency APVV Grant APVV-16-0066, and VEGA Grants 1/0199/17 and 1/0380/18.

Compliance with ethical standards

Conflict of interest

All authors declare no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.CrossRefGoogle Scholar
  2. 2.
    Network Cancer Genome Atlas. Comprehensive molecular characterization of human and rectal cancer. Nature. 2012;18:330–7.CrossRefGoogle Scholar
  3. 3.
    Mahasneh A, Al-Shaheri F, Jamal E. Molecular biomarkers for an early diagnosis, effective treatment and prognosis of colorectal cancer: current updates. Exp Mol Pathol. 2017;102:475–83.CrossRefGoogle Scholar
  4. 4.
    Pilati C, Shinde J, Alexandrov LB, et al. Mutational signature analysis identifies MUTYH deficiency in colorectal cancers and adrenocortical carcinomas. J Pathol. 2017;242:10–5.CrossRefGoogle Scholar
  5. 5.
    Cohen R, Sroussi M, Pilati C, Houry S, Laurent-Puig P, André T. Unresectable metastatic colorectal cancer patient cured with cetuxomab-based chemotherapy: a case report with new molecular insights. Gastrointest Oncol. 2018;9:E23–7.CrossRefGoogle Scholar
  6. 6.
    Palles C, Cazier JB, Howarth KM, et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet. 2013;45:136–44.CrossRefGoogle Scholar
  7. 7.
    Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18:325–32.CrossRefGoogle Scholar
  8. 8.
    Church DN, Briggs SE, Palles C, Collaborators NSECG, Kaur K, Taylor J, Tomlinson IP, et al. DNA polymerase ε and δ exonuclease domain mutations in endometrial cancer. Hum Mol Genet. 2013;22:2820–8.CrossRefGoogle Scholar
  9. 9.
    The Cancer Genome Atlas Network. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67–73.CrossRefGoogle Scholar
  10. 10.
    Song Z, Cheng G, Xu C, Wang W, Shao Y, Zhang Y. Clinicopathological characteristics of POLE mutation in patients with non-small cell lung cancer. Lung Cancer. 2018;118:57–61.CrossRefGoogle Scholar
  11. 11.
    Rayner E, van Gool IC, Palles C, et al. A panoply of errors: polymerase proofreading domain mutations in cancer. Nat Rev Cancer. 2016;16:71–81.CrossRefGoogle Scholar
  12. 12.
    Domingo E, Freeman-Mills L, Rayner E, et al. Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. Lancet Gastroenterol Hepatol. 2016;1:207–16.CrossRefGoogle Scholar
  13. 13.
    Guerra J, Pinto C, Pinto D, et al. POLE somatic mutations in advanced colorectal cancer. Cancer Med. 2017;6:2966–71.CrossRefGoogle Scholar
  14. 14.
    Howitt BE, Shukla SA, Sholl LM, et al. Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol. 2015;1:1319–23.CrossRefGoogle Scholar
  15. 15.
    Le DT, Durham JN, Smith KN, et al. PD-1 blockade in tumors in tumors with mismatch—repair deficiency. N Engl J Med. 2015;372:2509–20.CrossRefGoogle Scholar
  16. 16.
    Gong J, Wang C, Lee PP, Chu P, Fakih M. Response to PD-1 blockade in microsatellite stable metastatic colorectal cancer harboring a POLE mutations. J Natl Canc Netw. 2017;15:142–7.CrossRefGoogle Scholar
  17. 17.
    Ahn SM, Ansari AA, Kim J, et al. The somatic POLE P286R mutation defines a unique subclass of colorectal cancer featuring hypermutation, representing a potential genomic biomarker for immunotherapy. Oncotarget. 2017;7:68638–49.Google Scholar
  18. 18.
    Connell LC, Mota JM, Braghiroli MI, Hoff PM. The rising incidence of younger patients with colorectal cancer: questions about screening, biology, and treatment. Curr Treat Options Oncol. 2017;18:23.CrossRefGoogle Scholar
  19. 19.
    Schellerer VS, Merkel S, Schumann SC, et al. Despite aggressive histopathology survival is not impaired in young patients with colorectal cancer: CRC in patietns under 50 years of age. Int J Colorectal Dis. 2012;27:71–9.CrossRefGoogle Scholar
  20. 20.
    Murphy CC, Singal AG. Establishing a research agenda for early-onset colorectal cancer. PLOS Med. 2018;15:e1002577.CrossRefGoogle Scholar
  21. 21.
    Temko D, Van Gool IC, Rayner E, et al. Somatic POLE exonuclease domain mutation are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response. J Pathol. 2018;245:283–96.CrossRefGoogle Scholar
  22. 22.
    Kašubová I, Kalman M, Jašek K, et al. Stratification of patients with colorectal cancer without the recorded family history. Oncol Lett. 2019;17:3649–56.Google Scholar
  23. 23.
    Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 7th ed. New York: Wiley; 2009.Google Scholar
  24. 24.
    Edge SB, Byrd SR, Compton CC. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.Google Scholar
  25. 25.
    Jenkins MA, Hayashi S, O’Shea AM, et al. Colon Cancer Family Registry. Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population—based study. Gastroenterology. 2007;133:48–56.CrossRefGoogle Scholar
  26. 26.
    Hyde A, Fontaine D, Stuckless S, et al. A histology-based model for predicting microsatellite instability in colorectal cancers. Am J Surg Pathol. 2010;34:1820–9.CrossRefGoogle Scholar
  27. 27.
    Malicherova B, Burjanivova T, Grendar M, et al. Droplet digital PCR for detection of BRAF V600E mutation in formalin-fixed, paraffin-embedded melanoma tissues: a comparison with Cobas 4800, Sanger sequencing, and allele-specific PCR. Am J Transl Res. 2018;10:3773–81.Google Scholar
  28. 28.
    Jasek K, Buzalkova V, Minarik G, et al. Detection of mutations in the BRAF gene in patients with KIT and PDGFRA wild-type gastrointestinal stromal tunors. Virchows Arch. 2017;470:29–36.CrossRefGoogle Scholar
  29. 29.
    Esteban-Jurado C, Giménez-Zaragoza D, Muñoz J, et al. POLE and POLD1 screening in 155 patients with multiple polyps and early-onset colorectal cancer. Oncotarget. 2017;8:26732–43.CrossRefGoogle Scholar
  30. 30.
    Wang C, Gong J, Tu TY, Lee PP, Fakih M. Immune profiling of microsatellite instability-high and polymerase ε (POLE)- mutated metastatic colorectal tumors identifies predictors of response to anti-PD-1 therapy. J Gastrointest Oncol. 2018;9:404–15.CrossRefGoogle Scholar
  31. 31.
    Grasso CS, Giannakis M, Wells DK, et al. Genetic mechanisms of immune evasion in colorectal cancer. Cancer Discov. 2018;8:730–49.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Zora Lasabová
    • 1
    • 2
    Email author
  • Michal Kalman
    • 3
  • Veronika Holubeková
    • 1
  • Marián Grendár
    • 4
  • Ivana Kašubová
    • 1
  • Karin Jašek
    • 1
  • Sandra Meršaková
    • 1
  • Bibiana Malicherová
    • 1
  • Denis Baranenko
    • 5
  • Mariusz Adamek
    • 6
  • Peter Kruzliak
    • 7
    Email author
  • Lukáš Plank
    • 3
  1. 1.Division of Oncology, Biomedical Center Martin, Jessenius Faculty of Medicine in MartinComenius University in BratislavaMartinSlovakia
  2. 2.Department of Molecular Biology and Genomics, Jessenius Faculty of Medicine in MartinComenius University in BratislavaMartinSlovakia
  3. 3.Department of Pathological Anatomy, Jessenius Faculty of Medicine University Hospital in MartinComenius University in BratislavaMartinSlovakia
  4. 4.Department of Bioinformatics, Biomedical Center Martin, Jessenius Faculty of Medicine in MartinComenius University in BratislavaMartinSlovakia
  5. 5.International Research Centre “Biotechnologies of the Third Millennium”ITMO UniversitySaint-PetersburgRussian Federation
  6. 6.Department of Thoracic Surgery, Faculty of Medicine and DentistryMedical University of SilesiaKatowicePoland
  7. 7.Department of Internal MedicineBrothers of Mercy HospitalBrnoCzech Republic

Personalised recommendations